The 6th Annual MarketsandMarkets Next Gen Immuno-Oncology Conference, which will be held on the 22nd and 23rd of June 2023 at the Hilton Boston Logan Airport in Boston, will cover the difficulties and future directions in IO research. The congress seeks to bring together academicians, researchers, and scientists from research institutes, pharmaceutical, bio-pharmaceutical, and biotechnology firms to discuss the most recent developments in ADC, Bispecific Antibodies, Cellular Therapy, and Immune Checkpoint Inhibitors development.
This congress would also include diverse combination techniques, pre-clinical and translational immune-oncology advances, cellular and viral therapy updates, vaccine development, and customized immunotherapy. Keynote speeches, Brainstorming Panel Discussions, and Case Studies will allow stakeholders to discuss and comprehend the issues at hand, as well as come up with solutions. With over 20 presenters from pharma, bio-pharma, and biotech businesses from across the world, the congress will cover the most recent developments in the development of ADCs, Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors, and Cellular Therapy.
Conference Name: Next-Gen Immuno-Oncology Conference
Conference Time: June 22-23, 2023
Conference Venue: Hilton Boston Logan Airport, Boston
DetaiBio Booth: #14
Detai Bioscience, Inc. (“DetaiBio”), is a CRO vendor focusing on antibody discovery and functional protein research field. DetaiBio is aiming to provide high quality and economic offer service to speed up life science for our client in different fields, such as antibody drug discovery, in-vitro diagnosis and academic research.
The main services offer by DetaiBio:
——SingleB® for antibody/VHH discovery service
——High-throughput recombinant antibody expression service (2 week delivery)
——Hybridoma sequencing service
——Customized protein expression service ( E.coli, Mammalian)